Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Breast Milk of Healthy Lactating Women
NCT06720714Phase 1Completed
- Sponsor
- UCB
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoint: Concentration of Rozanolixizumab in Breast Milk Over a 7-day Sampling Period. Started Dec 2024; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06720714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720714.